Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BS006 oncolytic virus in advanced solid tumors
NCT05938296Phase 1Suspended
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BS-006 in melanoma, cutaneous squamous cell carcinoma (cSCC) and solid tumor, sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd. Primary endpoints: Adverse Event at 1 year, Serious Adverse Event at 1 year and 1 more. Started Dec 2023; status: suspended.
02
Drugs
BS-006
03
Conditions
melanomacutaneous squamous cell carcinoma (cSCC)solid tumor
Beyond the preview
Go deeper on NCT05938296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938296.